Volume 132, Issue 5 pp. 1133-1145
Epidemiology

Global estimates of cancer prevalence for 27 sites in the adult population in 2008

Freddie Bray

Corresponding Author

Freddie Bray

Section of Cancer Information, International Agency for Research on Cancer, Lyon, France

Tel.: +33-4-72-73-84-53, Fax: +33-4-72-73-86-96

Section of Cancer Information, International Agency for Research on Cancer, 150 cours Albert Thomas, F-69372 Lyon, Cedex 08, FranceSearch for more papers by this author
Jian-Song Ren

Jian-Song Ren

Section of Cancer Information, International Agency for Research on Cancer, Lyon, France

Search for more papers by this author
Eric Masuyer

Eric Masuyer

Section of Cancer Information, International Agency for Research on Cancer, Lyon, France

Search for more papers by this author
Jacques Ferlay

Jacques Ferlay

Section of Cancer Information, International Agency for Research on Cancer, Lyon, France

Search for more papers by this author
First published: 03 July 2012
Citations: 1,288

Abstract

Recent estimates of global cancer incidence and survival were used to update previous figures of limited duration prevalence to the year 2008. The number of patients with cancer diagnosed between 2004 and 2008 who were still alive at the end of 2008 in the adult population is described by world region, country and the human development index. The 5-year global cancer prevalence is estimated to be 28.8 million in 2008. Close to half of the prevalence burden is in areas of very high human development that comprise only one-sixth of the world's population. Breast cancer continues to be the most prevalent cancer in the vast majority of countries globally; cervix cancer is the most prevalent cancer in much of Sub-Saharan Africa and Southern Asia and prostate cancer dominates in North America, Oceania and Northern and Western Europe. Stomach cancer is the most prevalent cancer in Eastern Asia (including China); oral cancer ranks as the most prevalent cancer in Indian men and Kaposi sarcoma has the highest 5-year prevalence among men in 11 countries in Sub-Saharan Africa. The methods used to estimate point prevalence appears to give reasonable results at the global level. The figures highlight the need for long-term care targeted at managing patients with certain very frequently diagnosed cancer forms. To be of greater relevance to cancer planning, the estimation of other time-based measures of global prevalence is warranted.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.